Phcog.Net logo
Submit

BROWSE ALL JOURNALS

    SEE ALL 6 JOURNALS
    Journal of Pharmacology and PharmacotherapeuticsNOW IN
    Review

    Retrospection on the Role of Soluble Guanylate Cyclase in Parkinson’s Disease

    Mohankrishna Ghanta1, Elango Panchanathan2★, Bhaskar V. K. S. Lakkakula2, Anbumani Narayanaswamy2★ Corresponding author

    1. 1Departments of Pharmacology and Microbiology, Sri Ramachandra Medical College and Research Institute, Sri Ramachandra University, Porur, Chennai, Tamil Nadu, India.
    2. 2Department of Molecular Genetics, Research Division, Sickle Cell Institute Chhattisgarh, Raipur, Chhattisgarh, India.

    CORRESPONDENCE

    Elango Panchanathan

    Department of Molecular Genetics, Research Division, Sickle Cell Institute Chhattisgarh, Raipur, Chhattisgarh, India.

    drpelango@yahoo.com

    Received: 24-03-2017; Revised: 06-07-2017; Accepted: 09-08-2017.

    Volume 8, Issue 3 · pp. 87–91 · PUBLISHED 1 July 2017 · DOI: 10.4103/jpp.JPP_45_17

    View on J Pharmacol. Pharmacother. original site ↗

    ABSTRACT

    Soluble guanylate cyclase (sGC) is an important transducing enzyme of cyclic guanosine monophosphate (cGMP) signaling pathway in striatum which has been considered as a potential target for the treatment of Parkinson’s disease. Etiology of Parkinson’s disease is multifactorial, finally resulting in abnormal proteinopathies causing degeneration of nigrostriatal pathways. Understanding the pathological basis of Parkinson’s disease at molecular level is still an achievable target for the researchers and clinical practitioners. sGCs may be one of the causative factors resulting in Parkinson’s disease due to glutamate toxicity or other event. This review presents the literature from articles of past five decades nearly as still this enzyme protein and its role in Parkinson’s disease is not that clearly understood or presented till date. Recent interventions of this protein inhibition in the treatment of Parkinson’s disease preclinically gave a chance to review the literature about this enzyme and its correlation with factors causing Parkinson’s disease. We explored literature using PubMed and EMBASE for the role of sGC in Parkinson’s disease. Databases were searched using the following terms: Parkinson’s disease, neurotoxins, guanylate cyclase, sGC‑cGMP pathway, and neurodegeneration. This review listed out the factors that have probability for stimulating sGC which already have been listed as a neurotoxins causing Parkinson’s disease.

    KEYWORDS

    Open in new tab

    REFERENCES

    As published

    Showing references and in-text citations exactly as published.

      Cite this article

      SELECT FORMAT

      Ghanta, M., Panchanathan, E., Lakkakula, B. V. K. S., & Narayanaswamy, A. (2017). Retrospection on the Role of Soluble Guanylate Cyclase in Parkinson’s Disease. Journal of Pharmacology and Pharmacotherapeutics, 8(3), 87–91. https://doi.org/10.4103/jpp.JPP_45_17